Assessing the reduction of viral infectivity in HPV16/18-positive women after one, two, and three doses of Gardasil-9 (RIFT): Study protocol.

Autor: Victoria López-Codony, Álvaro de Andrés-Pablo, Angelica Ferrando-Díez, Maria Eulàlia Fernández-Montolí, Marta López-Querol, Sara Tous, Carlos Ortega-Expósito, Juan Carlos Torrejón-Becerra, Yolanda Pérez, Anna Ferrer-Artola, Josep Maria Sole-Sedeno, Clara Grau, Blas Rupérez, Maria Saumoy, Mónica Sánchez, Paula Peremiquel-Trillas, Laia Bruni, Laia Alemany, Francesc Xavier Bosch, Miquel Angel Pavón

Publikováno v: PLoS ONE, Vol 19, Iss 5, p e0304080 (2024)

Human Papillomavirus (HPV) prophylactic vaccination has proven effective in preventing new infections, but it does not treat existing HPV infections or associated diseases. Hence, there is still an important reservoir of HPV in adults, as vaccination

Externí odkaz: https://doaj.org/article/f7eff85e150f40349f9d8665f25785c9

Mpox: Clinical Outcomes and Impact of Vaccination in People with and without HIV: A Population-Wide Study

Autor: Raquel Martín-Iguacel, Carles Pericas, Andreu Bruguera, Gemma Rosell, Erica Martínez, Yesika Díaz, Lucia Alonso, Daniel Kwakye Nomah, Jose Luis Blanco, Pere Domingo, Patricia Álvarez-López, Maria Saumoy Linares, Consuelo Vilades Laborda, Arantxa Mera, Sonia Calzado Isbert, Isik Somuncu Johansen, José M. Miró, Jordi Casabona, Josep M. Llibre

Publikováno v: Microorganisms, Vol 11, Iss 11, p 2701 (2023)

We investigated differences in mpox clinical outcomes in people with HIV (PWH) and without HIV (PWoH) and the impact of vaccination in Catalonia, Spain. We used surveillance data and the PISCIS HIV cohort. We included all confirmed mpox cases (May–

Externí odkaz: https://doaj.org/article/13501b706eaf4ce895ecee9a4381e21c

Lipids, biomarkers, and subclinical atherosclerosis in treatment-naive HIV patients starting or not starting antiretroviral therapy: Comparison with a healthy control group in a 2-year prospective study.

Autor: Silvana Di Yacovo, Maria Saumoy, José Luís Sánchez-Quesada, Antonio Navarro, Dmitri Sviridov, Manuel Javaloyas, Ramon Vila, Anton Vernet, Hann Low, Judith Peñafiel, Benito García, Jordi Ordoñez-Llanos, Daniel Podzamczer

Publikováno v: PLoS ONE, Vol 15, Iss 8, p e0237739 (2020)

ObjectiveTo assess the effect of HIV infection and combined antiretroviral therapy (c-ART) on various proatherogenic biomarkers and lipids and to investigate their relationship with subclinical atherosclerosis in a cohort of treatment-naive HIV-infec

Externí odkaz: https://doaj.org/article/01c0f7a1f1594b7b929ba67169cd5166

Doravirine Concentrations and Human Immunodeficiency Virus Type 1 RNA in the Genital Fluids of Virologically Suppressed Adults Switching to Doravirine Plus Emtricitabine/Tenofovir Alafenamide

Autor: Sofía, Scévola, Arkaitz, Imaz, Mackenzie L, Cottrell, Jordi, Niubo, Brian, Van Horne, Juan, Tiraboschi, Maria, Saumoy, Sandra, Morenilla, Irene, Soriano, Angela D M, Kashuba, Daniel, Podzamczer

Publikováno v: Clinical Infectious Diseases. 75:2012-2015

Doravirine (DOR) concentrations and HIV-1 RNA were evaluated in genital fluids from adults with HIV on stable therapy who switched to DOR + FTC/TAF. High protein-unbound DOR concentrations were observed in both seminal plasma and cervicovaginal fluid

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::081c1e68c431e5c709755f905b5cdfbe
https://doi.org/10.1093/cid/ciac410

Atherogenicity of low-density lipoproteins after switching from a protease inhibitor to dolutegravir: a substudy of the NEAT022 study

Autor: Maria Saumoy, Jose Luís Sánchez-Quesada, Lambert Assoumou, José Maria Gatell, Ana González-Cordón, Giovanni Guaraldi, Pere Domingo, Andrea Giacomelli, Jérôme Connault, Christine Katlama, Mar Masiá, Jordi Ordónez-Llanos, Anton Pozniak, Esteban Martínez, Daniel Podzamczer

Publikováno v: JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau

Background The aim of this study was to investigate whether switching from a ritonavir-boosted PI-based regimen to a dolutegravir-based regimen improved the atherogenic properties of LDL particles in patients with HIV. Methods This was a substudy of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eab9c9f7f5e3360a0ae1b6c408900ac2
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=13534